Curative Effect Observation Of Treating Multiple Sclerosis With Simvastatin And Corticosteroid And Its Effect On Serum Levels Of Il-6

Objective:In this study we observed the clinical effect of Simvastatin and corticosteroid on multiple sclerosis (MS) in acute stage and the change of serum levels of IL-6 before and since the treatment, and discuss the effect and mechanism of Simvastatin in the adjuvant treatment of MS.Method:39 cases of inpatients of MS who accord with inclusion criteria were randomly divided into two groups:treatment group (n=19) and control group (n=20). The control group was treated by routine treatment with intravenous dripping of methylprednisolone (MPS); the treatment group was treated by Simvastatin 40mg/d plus the routine treatment. The Expanded Disability Status Scale (EDSS) scores of two groups before thetreatment and in the 7th,14th,21st,28th days since the commencement of the treatment were recorded and compared, and the serum levels of interleukin-6 (IL-6) before and since the treatment (the 7th, 14th,21st,28th days) were determined by enzyme linked immunosorbent assay (ELISA). All the experimental results were analyzed with statistic soft package of SPSS 13.0; the data differences between two groups were compared by t-test, and it would have no statistics significance unless p<0.05.Results:The EDSS scores of the treatment group and the control group on the 7th,14th,21st,28th days declined compared with the values before the treatment,and the difference had statistics meaning (p<0.05); Compared with the values before the treatment, the two groups' serum levels of IL-6 on the 7th,14th,21st,28th days had declined since the treatment (p<0.05),and the difference had statistics meaning (p<0.05).Comparing the treatment group with control group, the difference of the declines of EDSS scores on the 7th and 14th days since the treatment had no statistics meaning (p>0.05), but the declines of EDSS scores on the 21st and 28th days between two groups were obviously different (P<0.05), of which the treatment group's was bigger than the control group's.comparing the treatment group with control group, serum levels of IL-6 of two groups on the 7th day since the treatment were not distinctly different (p>0.05), but on the 14th,21st,28th days the treatment group's kept under the control group's (P<0.05).Conclusion:1. Simvastatin has adjuvant treatment function on the therapy of multiple sclerosis in acute stage;2. Reducing the serum levels of IL-6 may be one of the mechanisms of Simvastatin in the adjuvant treatment of MS.